Magnetic Resonance Imaging Contrast Agents - Issues of Concern, Safety, and Efficacy
Alain L Fymat*
Institute Professor, International Institute of Medicine and Science, California, USA
*Corresponding Author: Alain L Fymat, Institute Professor, International Institute of Medicine and Science, California, USA
Received: March 20, 2021; Published: May 11, 2021
This article addresses important issues regarding the use of certain MRI contrast agents (linear and macrocylic gadolinium-based, non-gadolinium-based, iron-based, others). Specific attention is devoted to their corresponding safety and efficacy, and to their use or repeated use in patients with certain medical conditions.
Keywords: Imaging Agents; Linear Gadolinium-based; Macrocyclic Gadolinium-based; Non-gadolinium Based; Iron-based; Safety; Efficacy
- Centers for Disease Control and Prevention (CDC). "Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents". Morbidity and Mortality Weekly Report 56.7 (2007): 137-141.
- "EMA recommendations on Gadolinium-containing contrast agents". ema.europa.eu. Retrieved 2018-07-12. "Information on Gadolinium-Containing Contrast Agents". Fda.gov.
- "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings" (PDF). United States Food and Drug Administration. 2017-12-19.
- Fymat AL. “Magnetic Resonance Imaging with Nanocontrasting Materials”, Invited Address presented at the BIT's 4th Annual Congress in Nanomedicine, Shuzou, China, June 2013 (2013).
- “Magnetic Resonance Imaging Modalities with Nanocontrasting Materials”. Journal of Current Trends in Clinical and Medical Imaging 1.1 (2017): 1-4.
- Geraldes CFGC and Laurent S. "Classification and basic properties of contrast agents for magnetic resonance imaging". Contrast Media and Molecular Imaging1 (2009): 1-23.
- Grobner T. "Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?". Nephrology Dialysis Transplantation4 (2005): 1104-1108.
- Kanal E., et al. "ACR Guidance Document for Safe MR Practices: 2007". American Journal of Roentgenology6 (2007): 1447-1474.
- Koretsky Alan P and Silva Afonso C. “"Manganese-enhanced magnetic resonance imaging (MEMRI)". NMR in Biomedicine8 (2004): 527-531.
- Marckmann P., et al. "Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging". Journal of the American Society of Nephrology9 (2006): 2359-2362.
- Murphy KJ., et al. "Adverse reactions to gadolinium contrast media: A 1996 review of 36 cases". American Journal of Roentgenology4 (1996): 847-849.
- Qiao Jingjuan., et al. "Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents". Journal of Biological Inorganic Chemistry2 (2014): 259-270.
- Rinck PA. "Chapter 13 - Contrast Agents". Magnetic Resonance in Medicine (11th ed.). European Magnetic Resonance Forum. Retrieved 2020-07-31 (2017).
- Sudarshana DM., et al. "Manganese-Enhanced MRI of the Brain in Healthy Volunteers". American Journal of Neuroradiology8 (2019): 1309-1316.
- Xue Shenghui., et al. "Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers". Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology2 (2013): 163-179.
- Xue Shenghui., et al. "Design of ProCAs (Protein-Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers". Medicinal Research Reviews5 (2014): 1070-1099.
- Zhen Zipeng and Xie J . "Development of Manganese-Based Nanoparticles as Contrast Probes for Magnetic Resonance Imaging". Theranostics 1 (2012): 45-54.